ARTV biotech catalysts & pipeline

ARTIVA BIOTHERAPEUTICS INC · Data as of 2026-10-25

Upcoming catalysts

AlloNK (AB-101) — Interim data

H2 2026

Updated clinical data expected in the second half of 2026 from at least 20 patients with refractory rheumatoid arthritis (RA) treated with AlloNK and rituximab in the ongoing company-sponsored Phase 2a basket trial, each with at least six months of follow-up, including at least 10 patients who would meet key eligibility criteria for the Phase 3 registrational trial in refractory RA

Source filing

AlloNK (AB-101) — Interim data

H2 2026

Updated clinical data expected in the second half of 2026 from at least 10 patients with Sjögren disease (SjD)

Source filing

AlloNK (AB-101) — Interim data

H2 2026

at least five patients with systemic sclerosis (SSc), each with at least six months of follow-up

Source filing

AlloNK (AB-101) — Topline data

H2 2028

We are initiating the registrational trial in the second half of 2026 and expect to report primary efficacy data in the second half of 2028, with a potential BLA submission in 2029.

Source filing

AlloNK (AB-101) — NDA/BLA submission

2029

We are initiating the registrational trial in the second half of 2026 and expect to report primary efficacy data in the second half of 2028, with a potential BLA submission in 2029.

Source filing

Explore the free biotech catalyst calendar